KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Short-term Investments (2016 - 2025)

Biomarin Pharmaceutical has reported Short-term Investments over the past 17 years, most recently at $248.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 27.75% year-over-year to $248.9 million, compared with a TTM value of $248.9 million through Dec 2025, up 27.75%, and an annual FY2025 reading of $248.9 million, up 27.75% over the prior year.
  • Short-term Investments came in at $248.9 million for Q4 2025, up from $227.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $572.0 million in Q1 2023 to a low of $194.9 million in Q4 2024.
  • Median Short-term Investments over the past 5 years was $380.3 million (2021), compared with a mean of $371.9 million.
  • The sharpest move saw Short-term Investments surged 32.91% in 2022, then crashed 47.63% in 2024.
  • Over 5 years, Short-term Investments stood at $426.6 million in 2021, then surged by 32.91% to $567.0 million in 2022, then plummeted by 43.8% to $318.7 million in 2023, then crashed by 38.85% to $194.9 million in 2024, then rose by 27.75% to $248.9 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Short-term Investments are $248.9 million (Q4 2025), $227.7 million (Q3 2025), and $218.3 million (Q2 2025).